|Day Low/High||0.32 / 0.32|
|52 Wk Low/High||0.29 / 1.61|
New details were released Tuesday from the phase III study of Celgene's Abraxane in pancreatic cancer.
Expanding use of Abraxane into pancreatic cancer could net Celgene another $1 billion in revenue.
Celgene's Abraxane delays tumor growth in patients with advanced melanoma.
A study of Abraxane in pancreatic cancer generates a ton of buzz even with data still weeks away.
How best to invest in the next important clinical trial catalyst facing Celgene.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.